Lallemand SAS   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Rexdale ON Canada (1895)
Status: No NME R&D (1895)

Organization Overview

First Clinical Trial
2008
NCT00796393
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Institut Rosell Lallemand | Lallemand Bio-Ingredients | Lallemand Health Solutions | Lallemand Health Solutions, Inc. | Lallemand Human Nutrition | Lallemand Pharma International | Lallemand Pharma International AG

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 4)

Asthma (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Body Weight (Phase 2)

Compulsive Personality Disorder (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Diarrhea (Phase 4)

Dysentery (Phase 4)

Dyspepsia (Phase 3)

Emergencies (Phase 3)

Gastroenteritis (Phase 3)

Hyperalgesia (Phase 1)

Hyperkinesis (Phase 4)

Inflammation (Phase 1)

Irritable Bowel Syndrome (Phase 2)

Lung Diseases, Obstructive (Phase 4)

Obsessive-Compulsive Disorder (Phase 4)

Overweight (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Stress, Psychological (Phase 3)

Substance Withdrawal Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 22